| Sep 18 |
MRK
|
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript) |
| Sep 18 |
MRK
|
Merck’s Keytruda label expanded in the U.S. for mesothelioma |
| Sep 18 |
MRK
|
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) |
| Sep 18 |
MRK
|
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial |
| Sep 17 |
MRK
|
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study |
| Sep 17 |
MRK
|
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial |
| Sep 17 |
MRK
|
Merck, Daiichi post late-stage trial win for novel lung cancer therapy |
| Sep 17 |
MRK
|
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial |
| Sep 16 |
MRK
|
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC |
| Sep 16 |
MRK
|
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 |
| Sep 15 |
MRK
|
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) |
| Sep 15 |
MRK
|
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma |
| Sep 14 |
MRK
|
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report |
| Sep 14 |
MRK
|
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer |
| Sep 14 |
MRK
|
Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers? |
| Sep 14 |
MRK
|
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer |
| Sep 14 |
MRK
|
Merck & Co., Inc. (MRK): A Good Beginner Stock According to Analysts |
| Sep 14 |
MRK
|
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Sep 14 |
MRK
|
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer |
| Sep 14 |
MRK
|
TIGIT drug from iTeos shrinks lung tumors in trial |
